Intellia Therapeutics, Inc. (NTLA)

9.27 -0.28 (-2.93%) USD  |  NASDAQ  |  Dec 12, 11:31
More

Intellia Therapeutics Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for NTLA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. Upgrade
Regeneron Pharmaceuticals, Inc. Upgrade
Beam Therapeutics, Inc. Upgrade
Vertex Pharmaceuticals, Inc. Upgrade
Pacific Biosciences of California, Inc. Upgrade